Female, Older Adults, Sarcopenia
Conditions
Keywords
sarcopenia, green tea, exercise, quality of life, physical performance, health biomarkers
Brief summary
Introduction: One of the consequences of aging is the decrease in physical performance which can affect the quality of life of older people. Although physical exercise is beneficial in improving this problem, older women do not seem to benefit as much as men. In this sense, the use of ergonomic aids by women could compensate for these issues. Thus, green tea has shown beneficial effects on physical performance in athletes through, among others, improving blood flow and vasodilation, mitochondrial respiration, calcium management, glucose and amino acid uptake, lipid oxidation, modulation of muscle damage, antioxidant effect, and anabolic and catabolic hormones, activation of the hypothalamic-pituitary-adrenal axis, etc. Therefore, the deterioration of physical performance and quality of life of green tea. Objective: To analyze the effect of supplementation with 1 g/day green tea extract (500 mg of polyphenols) for 10 weeks on quality of life values, physical performance (grip strength, walking speed, and resistance), and health biomarkers (biochemical, hematological, and hormonal) in women over 60 years of age who follow a physical training program. Methods: A total of 20 female volunteers between 60 and 73 years old (age: 65.9±4.58 years, BMI: 25.09±3.24 and body fat percentage: 32.54±6.39) who followed a physical activity adapted to their age and abilities are the members of this study. The volunteers were divided into two groups: placebo (CG; n = 10) and supplemented with 1 g/day of green tea (GI; n = 10). Different physical tests were performed (grip strength, walking speed and resistance) and the quality of life questionnaire (WHOQOL-BREF) was passed and health biomarkers (biochemical, hematological, and hormonal) were analyzed at the beginning (T1) and at the end of the 10 weeks of intervention (T2).
Interventions
DIETARY_SUPPLEMENTGreen tea (Camellia sinensis) 1000 mg as extract
Two capsules per day; Each capsule includes Green Tea Leaf (Camellia sinensis) 5000 mg composed of 500 mg of green tea extract and 250 mg of polyphenols (epicatechin (EC), epigallocatechin (EGC), epicatechin gallato (ECG), and epigallocatechin gallato (EGCG))
OTHERPlacebo
Two capsules per day; Each capsule includes 100-mg maltodextrin capsules were used as a placebo to match the color and texture of the Green tea tablets to ensure blinding.
Sponsors
Sanidad de Castilla y León
Instituto de Neurociencia de Castillas y Leon
University of Valladolid
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)
Intervention model description
Parallel group placebo-controlled randomized clinical trial
Eligibility
Sex/Gender
FEMALE
Age
60 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* Older adult women between 60 and 80 years old, with the ability to carry out a physical activity program adapted to their age and health condition.
Exclusion criteria
1. Functional limitation using the Barthel scale (less than 100 = maximum score) and the Lawton-Brody scale (less than 8 = maximum value). 2. Acute/chronic heart failure with NYHA (New York Heart Association) scale \>II. 3. Uncontrolled hypertension (\>180/100 mm Hg). 4. Uncontrolled orthostatic hypotension. 5. Uncontrolled atrial or ventricular arrhythmias, aortic dissecting aneurysm, severe aortic stenosis, acute endocarditis/pericarditis. 6. Recent acute myocardial infarction (3 to 6 months) or unstable angina. 7. Acute thromboembolic disease. 8. Acute/chronic respiratory failure. 9. Moderate/severe chronic obstructive pulmonary disease (COPD) with Bodex index C or D. 10. Diabetes mellitus with acute decompensation or uncontrolled hypoglycemia. 11. Recent bone fracture (last month). 12. History of dementia (suspected by the MAP environment and diagnosed). 13. Previous supplementation with amino acids or other nutritional compounds to improve physical performance. 14. Any other circumstance that your doctor considers prevents physical activity.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Creatine kinase (CK) | first day of study and after 30 days of supplementation (end of study) | CK is an enzyme expressed by various tissues and cell types; markers of muscle damage |
| Lactate dehydrogenase (LDH) | first day of study and after 30 days of supplementation (end of study) | LDH is a catalytic enzyme found in many tissues of the body;markers of muscle damage |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Aspartate Aminotransferase (AST) | 1st and 30th days of the trial | markers of liver damage |
| Interleukin 6 (IL-6) | 1st and 30th days of the trial | inflammatory marker |
| C-reactive protein (PCR) | 1st and 30th days of the trial | inflammatory marker |
| Testosterone | 1st and 30th days of the trial | hormonal marker |
| Cortisol | 1st and 30th days of the trial | hormonal marker |
| Miostatin (GDF8) | 1st and 30th days of the trial | growth factor that limits the growth of muscle tissue |
| Myoglobin (Mb) | 1st and 30th days of the trial | Mb is a muscle heteroprotein |
| lipid peroxidation (LPO) | 1st and 30th days of the trial | lipid oxidation marker |
| Oxygen radical absorption (ORAC) | 1st and 30th days of the trial | antioxidant strength marker |
| Total antioxidant status (TAS) | 1st and 30th days of the trial | antioxidant capacity marker |
| Total antioxidant capacity (TAC) | 1st and 30th days of the trial | antioxidant capacity marker |
| Short Physical Performance Battery (SPPB) | 1st and 30th days of the trial | Test evaluates three aspects of mobility |
| World Health Organization Quality of Life - BREF (WHOQOL-BREF) | 1st and 30th days of the trial | a self-report questionnaire which assesses 4 domains of quality of life (QOL): physical health, psychological health, social relationships, and environment |
| advanced oxidation protein products (AOPP) | 1st and 30th days of the trial | amino acid oxidation marker |
| Alanine Aminotransferase (ALT) | 1st and 30th days of the trial | markers of liver damage |
Countries
Spain
Contacts
Primary ContactDiego Fernández Lázaro, Professor; PhD
Backup ContactCésar Ignacio Fernández Lázaro, Professor; PhD
Outcome results
None listed